Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NP201
NP201
Merck doubles down on NGM Bio pact but culls obesity drug
Fierce Biotech
Wed, 03/20/19 - 12:15 pm
Merck
R&D
NGM Biopharmaceuticals
NP201
NASH
obesity